MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

A breakthrough CAR-T cell therapy, Qartemi, has been approved for blood cancer patients in India, offering new hope to those ...

Pfizer has taken a $1.2 billion hit after reassessing the prospects of two antibody-drug conjugates (ADC) it picked up in the ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $49.4 million, has announced updated data from its Phase 2 clinical ...

MAIA Biotechnology (MAIA) announced updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, ...

Scientists at UC San Francisco have pioneered a groundbreaking approach to fighting cancer using engineered fat cells. By ...

I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision ...

Learn more about whether Blueprint Medicines Corporation or Zai Lab Limited is a better investment based on AAII's A+ ...